Allografting for chronic myeloid leukemia

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 369-376

  Savage, David G ^a   Goldman, John M ^b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ALLOGRAFT; BONE MARROW; CHRONIC MYELOID LEUKEMIA; HUMAN; LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; UMBILICAL CORD BLOOD;

EID: 0030732726     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00002     Document Type: Review

References (77)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Review: chronic myelogenous leukemia - a concise update. Blood 1993, 82:691-703.
2. Savage DG, Goldman JM: Approaches to the treatment of chronic myeloid leukemia. Intl J Hematol 1994, 60:1-21.
3. Clift RA: Marrow transplantation for chronic myeloid leukemia. In Technical and Biological Components of Marrow Transplantation. Edited by Buckner CD, Clift RA. Boston: Kluwer; 1995:1-42.
4. Savage DG, Goldman JM: Allogeneic stem cell transplantation in chronic myelogenous leukemia. In Medical Managment of Chronic Myelogenous Leukemia. Edited by Talpaz M, Kantarjian H. New York: Marcel Dekker; 1998, in press.
5. Szydlo RM, Goldman JM, Klein JP, Gale RP, Ash RC, Bach RH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, et al.: Results of allogeneic bone marrow transplantation for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997, 15:1767-1777. This International Bone Marrow Transplant Registry report presents data on over 2000 patients undergoing allogeneic SCT for acute leukemia and CML. Outcome was determined by stage of leukemia, donor-recipient relationship, and degree of HLA matching. For early leukemia, alternative donor transplants were more than twice as likely to fail compared to HLA-identical sibling allogeneic SCT.
6. Charron DJ: HLA matching in unrelated donor bone marrow transplantation. Curr Opin Hematol 1996, 3:416-422. An excellent review of HLA typing methods.
7. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995, 86:1606-1613.
8. Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NKC, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P: Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective. Blood 1996, 88:714-720.
9. Speiser DE, Tiercy J-M, Rufer N, Grundschober C, Gratwohl A, Chapuis B, Helg C, Lεliger C-C, Siren M-K, Roosnek E, Jeannet M: High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996, 87:4455-4462. Molecular HLA typing is of critical importance in unrelated allogeneic SCT. GVHD and transplant-related mortality were reduced and survival better in leukemic patients who had received marrow from donors matched by high-resolution typing.
10. Williams F, Mawhinney H, Middleton D: Application of an HLA-B PCR-SSOP typing method to a bone marrow donor registry. Bone Marrow Transplant 1997, 19:205-208.
11. Devergie A, Apperley JF, Labopin M, Madrigal A, Jacobsen N, Carreras E, Prentice HG, Jouet JP, Kolb H-J, et al.: European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1997, 20:11-20.
12. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith AG, Martin PJ, Hansen JA: Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997, 89:1818-1823.
13. Nagler A, Brautbar C, Slavin S, Bishara A: Bone marrow transplantation using unrelated and family donors: the Impact of HLA-C disparity. Bone Marrow Transplant 1996, 18:891-897.
14. Arguello R, Avakian H, Goldman JM, Madrigal JA: A novel method for simultaneous high resolution identification of HLA-A, B and Cw alleles. Proc Natl Acad Sci U S A 1996, 93:10961-10965.
15. Spencer A, Szydlo RM, Brookes PA, Kaminski E, Rule S, van Rhee F, Ward KN, Hale G, Waldmann H, Hows JM, Batchelor JR, Goldman JM: Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or 'in vivo' T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995, 86:3590-3597.
16. Schipper RF, D'Amaro J, Oudshoorn M: The probability of finding a suitable related donor for bone marrow transplantation in extended families. Blood 1996, 87:800-804.
17. Ottinger H, Beelen D, Sayer H, Schaefer UW, Grosse-Wilde H: Bone marrow transplantation from partially matched HLA-matched related donors in adults with leukaemia: the experience at the University Hospital of Essen, Germany. Br J Haematol 1996, 92:913-921.
18. Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, Gee AP: Use of partially mismatched related donors extends access to allogeneic marrow transplant Blood 1997, 89:3864-3872. Allogeneic SCT using HLA-mismatched family members has been associated with high morbidity and mortality. The South Carolina group has used intensive pretransplantation conditioning and T-cell depleted, mismatched family member grafts as treatment for high-risk acute leukemia and CML. Their results suggest that this is a feasible option in patients who lack an HLA-identical donor.
19. Munn RK, Henslee-Downey PJ, Romond EH, Marciniak EJ, Fleming DR, Messino MJ, Macdonald JS, Rayens MK, Harder EJ, Phillips GL, Thompson JS: Treatment of leukemia with partially matched related bone marrow transplantation. Bone Marrow Transplant 1997, 19:421-427.
20. Speiser DE, Hermans J, van Biezen A, Starobinski M, Jeannet M, Jacobsen N, Niederwieser D, Gratwohl A, Apperley JF: Haploidentical family member transplants for patients with chronic myeloid leukaemia: a report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997, 19:1197-1204.
21. Freytes CO, Beatty PG: Representation of Hispanics in the National Marrow Donor Program. Bone Marrow Transplant 1996, 17:323-327.
22. Abecasis MM, Machado AM, Boavida G, Silva MG, Lúcio P, Ambrósio A, Jorge ML: Haploidentical cord blood transplantation contaminated with maternal T cells in a patient with advanced leukaemia. Bone Marrow Transplant 1996, 17:891-895.
23. Fernández MN, Regidor C, Diez JL, Forés R, Sanjuán I, Briz M, Cabrera R: HLA haploidentical cord blood cell transplant in a 15-year-old, 50 kg weight patient: successful treatment for chronic myeloid leukemia after myeloid blastic transformation. Bone Marrow Transplant 1996, 17:1175-1178.
24. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
25. Laporte J-P, Gorin N-C, Rubinstein P, Lesage S, Portnoi M-F, Barbu V, Lopez M, Douay L, Najman A: Cord blood transplantation from an unrelated donor in an adult with chronic myelogenous leukemia. N Engl J Med 1996, 335:167-170. This French group reports an excellent outcome in an adult patient with advanced phase CML who received an umbilical cord blood transplant.
26. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NKC, McGlave PB, Sender L, Cairo MS: Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802.
27. Roncarolo MG, Bigler M, Ciuti E, Martino S, Tovo P-A: Immune responses by cord blood cells. Blood Cells 1994, 20:573-586.
28. DiGiusto DL, Lee R, Moon J, Moss K, O'Toole T, Voytovich A, Webster D, Mule JJ: Hematopoietic potential of cryopreserved and ex vivo manipulated umbilical cord blood progenitor cells evaluated in vitro and in vivo. Blood 1996, 87:1261-1271.
29. Goldman J: Peripheral blood stem cells for allografting. Blood 1995, 85:1413-1415.
30. Bacigalupo A, Van Lint MT, Valbonesi M, Lercari G, Carlier P, Lamparelli T, Gualandi F, Occhini D, Bregante S, Valeriani A, et al.: Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood 1996, 88:353-357.
31. Russell JA, Brown C, Bowen T, Luider J, Ruether JD, Stewart D, Chaudhry A, Booth K, Jorgenson K, Coppes MJ, et al.: Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996, 17:703-708.
32. Miflin G, Russell NH, Hutchinson RM, Morgan G, Potter M, Pagliuca A, Marsh J, Bell A, Milligan D, Lumley M, Cook G, Franklin I: Allogeneic perlpheral blood stem cell transplantation for haematological malignancies: an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997, 19:9-13.
33. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, et al.: Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994, 84:2036-2043.
34. Devergie A, Blaise D, Attal M, Tiguad JD, Jouet JP, Vemant JP, Bordigoni P, Ifrah N, Dauriac C, Cahn JY, et al.: Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen. A report from the French Society of Bone Marrow Graft (SFGM). Blood 1995, 85:2263-2268.
35. Demirer T, Buckner CD, Appelbaum FR, Bensinger WI, Sanders J, Lambert K, Clift R, Fefer A, Storb R, Slattery J: Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996, 17:341-346. Unpredictable busulfan bioavailability may pose significant problems in patients receiving busulfan and cyclophosphamide conditioning. The Seattle group reports that adjustment of the busulfan dose according to plasma level affords excellent myeloablation and immunosuppression and less toxicity than seen with standard busulfan administration.
36. Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, Mellander L, Jacobsen N for the Nordic Bone Marrow Transplantation Group: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994, 83:2723-2730.
37. Topolsky D, Crilley, Styler, MJ, Bulova S, Brodsky I, Marks DI: Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only conditioning regimen: low incidence of failed engraftment and severe acute GVHD. Bone Marrow Transplant 1996, 17:549-554.
38. Bertz H, Potthoff K, Mertelsmann R, Finke J: Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997, 19:1169-1173.
39. Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J: Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplant 1996, 17:685-689.
40. Corcoran MC, Press OW, Matthews DC, Appelbaum FR, Bernstein ID: The role of radioimmunotherapy in bone marrow transplantation. Curr Opin Hematol 1996, 3:438-445. A detailed review of novel radiotherapeutic approaches to conditioning therapy for allogeneic SCT.
41. 52Fe before bone marrow transplantation. Bone Marrow Transplant 1997, 19:191-196.
42. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536. Many patients with CML are not eligible for allogeneic SCT because of age or other comorbid conditions. The Houston group has introduced a relatively innocuous fludarabine-based regimen as conditioning prior to T-cell-depleted allogeneic SCT followed by donor lymphocyte transfusion. This approach may make transplantation a feasible option for larger numbers of patients with hematologic malignancies.
43. Gratwohl A, Hermans J, von Biezen A, Arcese W, Debusscher L, Ernst P, Ferrant A, Frassoni F, Gahrton G, Iriondo A, et al.: Splenic irradiation before bone marrow transplantation. Br J Haematol 1996, 95:494-500.
44. Horowitz MM, Rowlings PA, Passweg JR: Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996, 17(suppl 3):S5-S6. A recent update from the IBMTR presenting survival and relapse data for HLA-identical sibling bone marrow transplantation for CML for the years 1987-1994.
45. Savage DG, Szydlo RM, Chase A, Appertey JF, Goldman JM: Bone marrow transplantation for chronic myeloid leukemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997, 99:30-35.
46. Copelan EA, Penza SL, Elder PJ, Belt PS, Scholl MD, Hehmeyer DM, Ezzone SA, Bechtel TP, Avalos BR: Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia. Bone Marrow Transplant 1996, 18:907-911.
47. Lipton JH, Messner HA, Curtis JE, Atkins HL, Minden MD: Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant: a pilot study. Eur J Haematol 1996, 57:42-45.
48. Gratwohl A, Hermans J: Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996, 17(suppl 3):S7-S9.
49. Enright H, Daniels K, Arthur DC, Dusenbery KE, Kersey JH, Kim T, Miller WJ, Ramsay NKC, Vercellotti GM, Weisdorf DJ, McGlave PB: Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant 1996, 17:537-542.
50. Kolb H-J, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese A, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
51. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, Castro-Malaspina H, Childs BH, Gillio AP, Keman NA, et al.: Adoptive Immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
52. Mavroudis D, Barrett J: The graft-versus-leukemia effect. Curr Opin Hematol 1996, 3:423-429. A superb review that discusses donor lymphocyte transfusion and therapeutic modalities designed to exploit the graft-versus-leukemia effect.
53. Van Rhee F, Kolb H: Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol 1995, 2:423-430.
54. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996, 87:2195-2204.
55. Bacigalupo A, Soracco M, Vasallo F, Abate M, Van Lint MT, Gualandi F, Lamparelli T, Occhini D, Mordini N, Bregante S, et al.: Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 19:927-932.
56. Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444. This report presents results of donor leukocyte infusions in 130 patients with relapsed hematologic malignancies at 25 North American institutions.
57. Keil F, Haas OA, Fritsch G, Kalhs P, Lechner K, Mannhalter C, Reiter E, Niederwieser D, Hoecker P, Greinix HT: Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997, 89:3113-3117. These German investigators present data that show an increased risk of marrow aplasia in patients with leukemic relapse who lack evidence of donor hematopoiesis at the time of donor leukocyte infusion.
58. Schattenberg A, Preijers F, Mensink E, Bär B, Schaap N, Geurts van Kessel A, van der Maazen R, de Witte T: Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase. Bone Marrow Transplant 1997, 19:1205-1212.
59. Van Rhee F, Savage DG, Blackwell J, Orchard K, Dazzi F, Lin F, Chase A, Bungey J, Cross NCP, Apperley JF, Szydlo R, Goldman JM: Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equivalence of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 1998, in press.
60. Fowler DH, Breglio J, Nagel G, Hirose C, Gress RE: Allospecific CD4+, Th1/Th2 and CD8+, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol Blood Marrow Transplant 1996, 2:118-125.
61. Glass B, Uharek L, Zeis M, Loeffler H, Mueller-Ruchholtz W, Gassmann W: Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells. Br J Haematol 1996, 93:412-420.
62. Wong EK, Eaves C, Klingemann H-G: Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12. Bone Marrow Transplant 1996, 18:63-71.
63. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ: Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996, 88:2450-2457.
64. Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, Lee M, Gajewski J, van Besien K, Khouri I, et al.: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995, 86:4337-4343.
65. Dermime S, Mavroudis D, Jiang Y-Z, Hensel N, Molldrem J, Barrett AJ: Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 19:989-999.
66. Van Rhee F, Lin F, Cross NC, Reid CD, Lakhani AK, Szydlo RM, Goldman JM: Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994, 14:609-612.
67. Cross NCP: Quantitative PCR techniques and applications. Br J Haematol 1995, 89:693-697.
68. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, Edmands S, Kirk J, Lee A, Kessler P, et al.: Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood 1995, 85:2632-2638.
69. Lin F, Kirkland MA, van Rhee F, Chase A, Coulthard S, Bungey J, Goldman JM, Cross NCP: Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996, 18:1147-1152. A detailed analysis of cytogenetic and molecular relapse following allogeneic SCT for CML
70. Lin F, van Rhee F, Goldman JM, Cross NCP: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996, 87:4473-4478.
71. Santini V, Zoccolante A, Bosi A, Guidi S, Saccardi R, Vannucchi AM, Martinazzo G, Bernabei PA, Ferrini PR: Detection of bcr/abl transcripts by RT-PCR and their calorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation. Haematologica 1996, 81:201-207.
72. Zhang JG, Lin F, Chase A, Goldman JM, Cross NCP: Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996, 87:2588-93.
73. El-Rifai W, Ruutu T, Vettenranta K, Temtamy S, Knuutila S: Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase-FISH study. Br J Haematol 1996, 92:365-369.
74. Barrett AJ, Mavroudis D, Molldrem J, Read EJ, Carter C, Dunbar C, Young NS: Optimizing the dose and timing of lymphocyte add-back in T-cell depleted BMT between HLA-identical siblings. Blood 1996, 88(suppl 1):460a.
75. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276:1719-1724. This paper describes a novel approach to treating leukemic relapse following allogeneic SCT. A viral "suicide gene" is transduced into donor lymphocytes ex vivo; the lymphocytes are then infused into the relapsing patient to confer GVL effect. Those patients who develop severe GVHD are given ganciclovir, which eliminates the offending lymphocyte population.
76. Faber LM, van Luxemburg-Heijs SAP, Rijnbeek M, Willemze R, Falkenburg JHF: Minor histocompatibility antigen-specific leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of a-interferon. Biol Blood Marrow Transplant 1996, 2:31-36.
77. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche K-O, Andreeff M, Champlin RE: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997, 89:1133-1142.